Abstract
This case series demonstrates an excellent pathological response to neoadjuvant checkpoint inhibitor (CPI) therapy in patients with mismatch repair-deficient (dMMR) colorectal cancer, which has translated into exemplary short-term oncological outcomes. As well as validating the utility of neoadjuvant CPI therapy in dMMR colorectal cancer, it also opens the door to future study of limited resection in patients with tumours that would otherwise require multivisceral resection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.